CANNABIS
Cannabis-based medicinal extracts effective in managing spasticity, but not other symptoms of MS
Mult Scler. 2004 Aug;10(4):434-41.160 patients diagnosed with multiple sclerosis (MS) were randomly assigned to receive either cannabis-based medicinal extracts (CMBE), a mixture of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), or placebo through oromucosal spray for 6 weeks. Patients were assessed on the change in VAS score of their nominated primary symptom (PSS), time in seconds to walk 10m, and various other cognitive functioning tests. Results demonstrated that CMBE was effective in reducing symptoms in patients who nominated spasticity as their primary symptom, but did not significantly differ from placebo in reducing symptoms in patients who nominated spasm, bladder control, pain, and tremor as their primary symptom.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
